| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | AREG; SDGF; AREGB; Amphiregulin; AR; Colorectum cell-derived growth factor; CRDGF |
| Entrez GeneID | 374; |
| WB Predicted band size | 29kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human Amphiregulin. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于Amphiregulin抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：Amphiregulin promotes regulatory T cell-mediated immune tolerance
**作者**：Shimizu et al.
**摘要**：研究报道调节性T细胞(Treg)通过分泌Amphiregulin(AREG)抑制炎症并促进组织修复。利用特异性抗体阻断AREG后，Treg细胞的免疫调节功能显著下降，表明AREG抗体在调控免疫耐受中的潜在作用。
2. **文献名称**：Amphiregulin enhances allergic airway inflammation through group 2 innate lymphoid cells
**作者**：Zaiss et al.
**摘要**：研究证明Th2细胞分泌的AREG通过激活IL-33信号通路加剧过敏性哮喘。通过AREG中和抗体干预可显著减少气道嗜酸性粒细胞浸润，提示其作为过敏性疾病治疗靶点的可能性。
3. **文献名称**：Amphiregulin as a biomarker for resistance to EGFR-targeted therapy
**作者**：Busser et al.
**摘要**：探讨肿瘤微环境中AREG表达与EGFR抑制剂耐药性的关联。研究利用AREG抗体检测患者样本，发现高表达AREG与治疗耐药性相关，为联合抗体治疗提供理论依据。
---
以上文献覆盖免疫调控、过敏疾病及肿瘤治疗领域，均通过特异性抗体阐明AREG的病理生理机制或应用潜力。如需扩展可补充具体实验模型(如小鼠/临床样本)或抗体应用细节。
Amphiregulin (AREG), a member of the epidermal growth factor (EGF) family, functions as a ligand for the epidermal growth factor receptor (EGFR). It plays critical roles in cell proliferation, differentiation, and survival, with involvement in tissue repair, inflammatory responses, and cancer progression. AREG is synthesized as a transmembrane precursor protein that undergoes proteolytic cleavage to release its active soluble form, enabling interaction with EGFR and activation of downstream signaling pathways like MAPK and PI3K/AKT. Its dysregulation is associated with various cancers, including colorectal, breast, and lung cancers, where it promotes tumor growth, metastasis, and therapy resistance.
Antibodies targeting AREG are essential tools for studying its expression, localization, and function. Polyclonal and monoclonal anti-AREG antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA to detect AREG levels in tissues, cell lysates, or biological fluids. Some antibodies specifically recognize the mature soluble form or the precursor protein, aiding in research on AREG processing and activation. Additionally, neutralizing antibodies are employed to inhibit AREG-EGFR interactions in functional studies, helping dissect its role in pathological processes like tumorigenesis or chronic inflammation.
Research applications of AREG antibodies extend to exploring therapeutic potential. Preclinical studies investigate their utility in blocking oncogenic signaling or modulating immune responses. AREG’s dual role in tissue repair and disease progression also makes it a biomarker of interest in regenerative medicine and cancer diagnostics. Antibody specificity across species (e.g., human, mouse) ensures relevance in both clinical and experimental models, supporting translational research aimed at targeting the EGFR axis in disease.
×
